<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538704</url>
  </required_header>
  <id_info>
    <org_study_id>2018ECFerSp</org_study_id>
    <nct_id>NCT03538704</nct_id>
  </id_info>
  <brief_title>Effect of Fertility-sparing Therapy of Early Endometrial Cancer</brief_title>
  <acronym>ECFerSp</acronym>
  <official_title>Effect of Fertility-sparing Therapy of Early Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal and Child Health Hospital of Hubei Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of Fertility-sparing Therapy of Early
      Endometrial Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi center, open, randomized, controlled clinical trial. All
      endometrial cancer (EC) or atypical hyperplasia (AH) patients who met the fertility-sparing
      indications in the hospitals involved in this study were recruited. Then the investigators
      conducted assessment, treatment and follow up according to the standard procedure. General
      information, therapeutic regimen, side effects, oncological and pregnant results were
      collected for risk factors analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>Histologically shows absence of pathological hyperplasia or carcinoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>Pregnancy test shows pregnancy after complete response.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>Pathology shows atypical hyperplasia or carcinoma again after complete response.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Endometrial Cancer</condition>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>BMI≥25 group with metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI≥25 group without metformin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin is given to patients 1-1.5g/d.</description>
    <arm_group_label>BMI≥25 group with metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ages of no more than 40

          -  with a strong desire of fertility preservation

          -  International Federation of Gynecology and Obstetrics (FIGO) 2009 stage Ⅰa grade 1~2
             with lesion confined in endometrium

          -  pathology expression of progestin receptors (PRs) and estrogen receptors

        Exclusion Criteria:

          -  not eligible for pregnancy or delivery

          -  evidence of suspected extrauterine or distant metastasis

          -  complicated with any other malignancy

          -  severe medical complications

          -  contraindication of oral progestin

          -  uncontrolled epilepsy, central nervous system disease or mental disorder history in
             patients which Influence clinical research compliance judging by the researcher.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianliu Wang, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Obstetrics and Gynecology, Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianliu Wang, Professor</last_name>
    <phone>010-88324381</phone>
    <email>wangjianliu1203@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rong Zhou, Professor</last_name>
    <phone>010-88324350</phone>
    <email>zhourong@pku.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianliu Wang, Professor</last_name>
      <phone>010-88324381</phone>
      <email>wangjianliu1203@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012 Oct;207(4):266.e1-12. doi: 10.1016/j.ajog.2012.08.011. Epub 2012 Aug 10. Review.</citation>
    <PMID>23021687</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial cancer</keyword>
  <keyword>Atypical hyperplasia</keyword>
  <keyword>Fertility-preserving</keyword>
  <keyword>Remission time</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Progesterone receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

